Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Bio-Path Holdings (BPTH) Share Price

Media headlines about Bio-Path Holdings (NASDAQ:BPTH) have been trending somewhat positive recently, Accern Sentiment reports. Accern rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Bio-Path Holdings earned a news impact score of 0.08 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.7790638513684 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Shares of Bio-Path Holdings (BPTH) opened at 0.345 on Wednesday. The stock’s 50 day moving average price is $0.31 and its 200 day moving average price is $0.49. The firm’s market capitalization is $34.52 million. Bio-Path Holdings has a one year low of $0.25 and a one year high of $1.50.

Bio-Path Holdings (NASDAQ:BPTH) last announced its quarterly earnings results on Thursday, August 10th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.01). Analysts expect that Bio-Path Holdings will post ($0.08) EPS for the current fiscal year.

A number of equities research analysts have commented on BPTH shares. HC Wainwright set a $5.00 price objective on Bio-Path Holdings and gave the stock a “buy” rating in a research report on Friday, August 11th. ValuEngine lowered Bio-Path Holdings from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Finally, Zacks Investment Research lowered Bio-Path Holdings from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th.

COPYRIGHT VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Bio-Path Holdings (BPTH) Share Price” was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at

About Bio-Path Holdings

Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.

Insider Buying and Selling by Quarter for Bio-Path Holdings (NASDAQ:BPTH)

Receive News & Ratings for Bio-Path Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path Holdings Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply